TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02240186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprocessor Knee (MPK)
Description: MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Microprocessor Knee (NMPK)
Description: A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
Study: NCT03092596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-administered screening tool
Description: screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient health navigator-administered screening tool
Description: patient health navigator-administered screener

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient health navigator-assisted linkage to treatment
Description: patient health navigator-assisted linkage to substance abuse treatment
Study: NCT01118845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
Study: NCT01341587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telcare Blood Glucose Meter (BGM)
Description: Cellular enabled glucometer
Study: NCT01785433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 9.0 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 9.0 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 9.0 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIRIVA® HandiHaler® 18 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIRIVA® HandiHaler® 18 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIRIVA® HandiHaler® 18 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIRIVA® HandiHaler® 18 mcg/day
Study: NCT06624657

Intervention type: OTHER
Intervention: vitamin D supplements fo 16 weks
Description: subjects exercised by HIIT-exercise for 16 weeks

Intervention type: OTHER
Intervention: vitamin D supplements fo 16 weks
Description: subjects exercised by HIIT-exercise for 16 weeks

Intervention type: OTHER
Intervention: vitamin D supplements fo 16 weks
Description: subjects exercised by HIIT-exercise for 16 weeks

Intervention type: OTHER
Intervention: vitamin D supplements fo 16 weks
Description: subjects exercised by HIIT-exercise for 16 weeks
Study: NCT02566447

Intervention type: DEVICE
Intervention: Solana Trichomonas Assay Testing
Description: Specimen collection of urine and/or vaginal swabs for testing
Study: NCT03857399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin
Description: Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
Study: NCT04117191

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Doctor's Best L-Tryptophan
Description: 2g tryptophan loading once
Study: NCT03218709

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High-dose multi-vitamins with minerals
Description: The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
Study: NCT00402155

Intervention type: BEHAVIORAL
Intervention: Stress on visual discomfort
Description: Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
Study: NCT03218709

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-dose multi-vitamins with minerals
Description: The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hypouricemic tablets
Description: The hypouricemic tablets contained skipjack,salvia and rosemary extract.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets contained maltodextrin and tartrazine.
Study: NCT03532841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet
Description: Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablet of the same shape,color and taste will be given in the placebo arm
Study: NCT02917850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic hip flexors strengthening
Description: Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation 10/w during 6 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation 10/w during 6 weeks
Study: NCT03840174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160
Description: V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
Study: NCT01857856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
Study: NCT02973061

Intervention type: OTHER
Intervention: Questionnaires
Description: All participants families will fulfill a periodic questionnaire regarding attention, behaviour.

Intervention type: OTHER
Intervention: Questionnaires
Description: All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
Study: NCT02527161

Intervention type: DEVICE
Group type: OTHER
Intervention: ShapeMatch Cutting Guides with Triathlon
Description: All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
Study: NCT04099095

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Appointment
Description: The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Appointment
Description: After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
Study: NCT01056029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
Study: NCT02248701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Subjects receive testosterone (125 mg/week) by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Subjects receive finasteride (5 mg/day) orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Subjects receive placebo (weekly) by intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects receive placebo pill (daily) orally
Study: NCT00986830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FinESS Sinus Treatment
Study: NCT02702804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Training
Study: NCT04794309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training exercise
Description: circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Healthy high Fiber diet
Description: The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy high Fiber diet
Description: The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
Study: NCT00731068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: injection of 6cc into injured area of tendon

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: injection of 6 cc of saline into injured area
Study: NCT03328117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Over-encapsulated 100 mg imatinib mesilate tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo oral capsule
Study: NCT03143309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Non-health related messages delivered via WhatsApp 2-3 times per week.
Study: NCT03861949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cmH2O CPAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cmH2O CPAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-up position
Study: NCT00964184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01785433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 5 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 5 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 5 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiriva® Respimat® 5 mcg/day
Study: NCT01002625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845 / matched placebo
Description: PF-04457845 4 mg tablet once daily / matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845 / matched placebo
Description: PF-04457845 4 mg tablet once daily / matched placebo
Study: NCT01474330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study: NCT01956409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FCH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist
Study: NCT00500786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT006-AngQb
Study: NCT00850460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will consist of lactose and will be given one capsule once daily
Study: NCT04159194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
Study: NCT06120634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgical method
Description: After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plastibell method
Description: The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
Study: NCT00475917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL844
Description: Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: once-weekly 30-minute IV infusion
Study: NCT00703976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
Study: NCT02074930

Intervention type: DEVICE
Group type: OTHER
Intervention: Microporation by P.L.E.A.S.E. Professional / Prick needle
Study: NCT01049568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell Phone Intervention
Description: Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization.
Study: NCT01691131

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: Comparison of high intensity exercise training on land versus water.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: Comparison of high intensity exercise training on land versus water.
Study: NCT00703976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
Study: NCT02583282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iodopovidine
Description: 20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
Study: NCT03507803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Biofeedback
Description: Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
Study: NCT01171040

Intervention type: OTHER
Intervention: Echocardiography, including the measurements of left atrial (LA) distensibility
Description: The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
Study: NCT01145625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil
Description: half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Minoxidil
Description: one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
Study: NCT00964184

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification
Study: NCT01489176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson; Optison
Description: A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
Study: NCT00111501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Use Disorder
Description: Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Web-based intervention
Description: General psychoeducational Web-based smoking cessation intervention
Study: NCT02573168

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GeneSight Psychotropic (GEN)
Description: Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Enhanced-GeneSight Psychotropic (E-GEN)
Description: The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.